Poolbeg Pharma presents new deal with AI in developing new RSV drugs

Poolbeg Pharma PLC  Jeremy Skillington joins Proactive London to talk about their new deal – using a state of the art artificial intelligence tool to find new drug targets for respiratory syncytial virus (RSV).

Under the terms of a deal with OneThree Biotech, it will screen for putative treatments that focus in on the immune-response pathways, have a higher probability of clinical success and have the potential to prevent and/or treat infectious diseases. 

Skillington says their ‘OneThree Biotech’s AI analysis tools will allow us to break new ground in data-driven drug discovery, by allowing us to evaluate and interrogate human challenge trial data like never before’.

https://www.proactiveinvestors.co.uk/companies/news/975001/poolbeg-pharma-s-jeremy-skillington-presents-new-deal-with-ai-in-developing-new-rsv-drugs-975001.html